Aytu Biopharma is a specialty pharmaceutical company focusing on developing and commercializing novel therapeutics and consumer healthcare products. The company is pursuing clinical development of AR101, a protein kinase inhibitor candidate for rare genetic disorders, positioning itself in niche therapeutic areas with significant unmet medical needs.
Cyborg Score Rationale
Aytu trades at historically depressed valuations with significant stock price volatility and limited financial scale. While the company has FDA recognitions and an established product portfolio in ADHD and pediatric care, recent performance and market positioning suggest operational and commercial challenges requiring strategic improvement.
Top Insights
FDA granted Orphan Drug designation to Aytu BioPharma's AR101 for the treatment of vascular Ehlers-Danlos Syndrome
Cotempla XR-ODT is indicated for the treatment of ADHD in pediatric patients
Karbinal ER is an extended-release antihistamine suspension for treating allergic conditions in patients two years and above
Operates in high-volatility micro-cap segment with minimal institutional investor interest and limited research coverage
Named Competitors
Ritalin — ADHD treatment with methylphenidate
Adhansia — Extended-release ADHD medication
Concerta — Osmotic-release methylphenidate for ADHD
Recent Developments
FDA granted Orphan Drug designation to AR101 for vascular Ehlers-Danlos Syndrome treatment
Company changed its name from Aytu BioScience, Inc. to Aytu BioPharma, Inc. in March 2021
Open the full interactive Aytu BioPharma, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.